BELKIN Laser Finalizes Series B Funding Totalling $12.25M
PR84843
YAVNE, Israel, July 21, 2020 /PRNewswire=KYODO JBN/ --
-- One-Second Glaucoma Laser Treatment nearing reality for millions of Glaucoma patients
BELKIN Laser (https://c212.net/c/link/?t=0&l=en&o=2862152-1&h=190843196&u=https%3A%2F%2Fwww.belkin-laser.com%2F&a=BELKIN+Laser ),
the Israel-based start-up offering a 1-second, non-invasive glaucoma laser
treatment announced today that it has finalized its round B financing with an
oversubscription totaling $12.25M. Rimonci Capital (https://c212.net/c/link/?t=0&l=en&o=2862152-1&h=3068186025&u=http%3A%2F%2Fwww.rimonci.com%2F&a=Rimonci+Capital )
and Santen Ventures, Inc. (https://c212.net/c/link/?t=0&l=en&o=2862152-1&h=531033288&u=https%3A%2F%2Fwww.santenusa.com%2Fophthalmic-start-ups&a=Santen+Ventures%2C+Inc. ) co-led the round.
They were joined by BioLight Life Sciences (https://c212.net/c/link/?t=0&l=en&o=2862152-1&h=3066772374&u=https%3A%2F%2Fbio-light.co.il%2F&a=BioLight+Life+Sciences ),
CR-CP Life Science Fund (https://c212.net/c/link/?t=0&l=en&o=2862152-1&h=3411984466&u=https%3A%2F%2Fwww.crunchbase.com%2Forganization%2Fcr-cp-life-science-fund%23section-overview&a=CR-CP+Life+Science+Fund ),
and C-Mer Eye Care Holdings (https://c212.net/c/link/?t=0&l=en&o=2862152-1&h=1684902856&u=http%3A%2F%2Fus.cmereye.com%2Findex.php%3Fg%3DPortal%26m%3DList%26a%3Dindex%26id%3D4&a=C-Mer+Eye+Care+Holdings ),
chaired by prominent ophthalmologist Dr. Dennis Lam.
CEO, Daria Lemann-Blumenthal said: "These investments signal to us that the
industry has trust in our technology which will impact the lives of millions of
glaucoma patients by opening a new viable drop-less treatment option. The funds
will be used to continue GLAUrious, our multi-center trial in Europe and
initiate trials in Asia. Our team's hard work has paid off and the good news is
that fast, easy and effective glaucoma treatment is one step closer for
millions of patients."
Globally 140M people have glaucoma or ocular hypertension (OHT), a leading
cause of blindness, but there are only 200,000 ophthalmologists and just 6,000
glaucoma specialists to treat them worldwide. BELKIN's automated, non-contact,
painless treatment (https://c212.net/c/link/?t=0&l=en&o=2862152-1&h=1304554160&u=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3D5CMI97G1tFA&a=BELKIN%27s+automated%2C+non-contact%2C+painless+treatment )
is activated by a touchscreen, controlled by a high-resolution image
acquisition algorithm and a proprietary eye tracker. This unique technology,
the brainchild of Prof. Michael Belkin, can be easily used by all ophthalmologists,
dramatically increasing the number of treated patients, both in central and rural areas,
while opening a new revenue stream for their clinics and hospitals.
Prior to this round the company raised $6.6M, which includes the Israel
Innovation Authority incubator grant at the Rad Biomed Accelerator
as well as the prestigious European Horizon 2020 grant of $3M. An additional
$2.5M investment was raised as part of the Series A financing round led by ZIG
Ventures (https://c212.net/c/link/?t=0&l=en&o=2862152-1&h=3281882532&u=https%3A%2F%2Fziggroup.com.sg%2F&a=ZIG+Ventures ) from Singapore.
Rimonci Capital CEO, Richel Liu said "As an early investor in both series A and
B, I'm extremely impressed by what BELKIN Laser has accomplished so far - from
proof of concept to positive first in human results and finally the nuanced
development process of the commercial device. The capability to give greater
access to glaucoma care is even closer."
Ken Araki, President of Santen Ventures, stated "Santen looks forward to
helping to drive new innovation that can enable more therapeutic choices for
patients, to, in turn, achieve better outcomes."
Liu Da, Managing Director at CR-CP Life Science Fund said "BELKIN's technology
aligns perfectly with our investment strategy of developing long-lasting,
profitable partnerships which will greatly benefit Chinese glaucoma patients".
Dennis Lam, chairman and CEO of C-MER, who will join BELKIN's medical advisory
board, states "BELKIN Laser's technology is very exciting, in particular their
unique solution to potentially treat angle closure glaucoma, which is prevalent
in Asian populations."
"BELKIN's DSLT will open up a new world for glaucoma patients," states Dr.
Richard Lindstrom, Chair of BELKIN Laser's Medical Advisory Board. "This next
generation SLT promises to make this procedure quicker and easier to perform,
allowing doctors to meaningfully help their patients."
About BELKIN Laser:
BELKIN Laser, an Israeli clinical-stage medical device company, established in
2013 and is developing an intuitive, automated one-second glaucoma laser treatment
aimed at promoting accessibility to first-line drop-less glaucoma care by
allowing any ophthalmologist and other eye care providers to treat many more
patients in any location. Visit the BELKIN Laser website (https://c212.net/c/link/?t=0&l=en&o=2862152-1&h=2348888078&u=http%3A%2F%2Fwww.belkin-laser.com%2F&a=BELKIN+Laser+website ) to learn more.
Related Links:
www.belkin-laser.com
BELKIN Laser LinkedIn (https://c212.net/c/link/?t=0&l=en&o=2862152-1&h=3232758087&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbelkin-laser-ltd%2F%3FviewAsMember%3Dtrue&a=BELKIN+Laser+LinkedIn )
BELKIN Laser YouTube (https://c212.net/c/link/?t=0&l=en&o=2862152-1&h=822763101&u=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUCb5LCywmfIlZpaJFZbTSHOQ&a=BELKIN+Laser+YouTube )
For Press Images, please visit our Dropbox (https://c212.net/c/link/?t=0&l=en&o=2862152-1&h=148025829&u=https%3A%2F%2Fwww.dropbox.com%2Fsh%2Fx8kelqxn0hvhhl5%2FAADKbI594f2JbESQKau2nq-Na%3Fdl%3D0&a=Dropbox )
SOURCE: BELKIN Laser
CONTACT: Nancy LeBosquain, Director of Communications, Nancy@belkin-laser.com,
+1 613-606-8003
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
